Please type a plus sign (+) inside this box +

Patent a Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/21 (6-98)	
Approved for use through 09/30/2000. OMB 0651-0031	+
nd Trademark Office: U.S. DEPARTMENT OF COMMERCE	
ad to recovered to a collection of information unlocalit displaces	

TRANSMITTAL FORM		Application Number	09/845,623		
		Filing Date	04/30/2001		
		First Named Inventor	Sudhir Agrawal		
(to be used for all correspondence after	initial filing)	Group Art Unit	1623		
		Examiner Name	Unknown		
Total Number of Pages in This Submis	sior	Attorney Docket Number	47508.508		
	ENCLOS	SURES (check all that app	olv)		
Fee Transmittal Form		nent Papers Application)	After Allowance Communication to Group		
Fee Attached	Drawing	ı(s)	Appeal Communication to Board of Appeals and Interferences		
Amendment / Response	Licensir	ng-related Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
After Final	Petition and Acc	Routing Slip (PTO/SB/69) companying Petition	Proprietary Information		
Affidavits/declaration(s)		to Convert to a mal Application	Status Letter		
Extension of Time Request	Power of Change Address	of Attorney, Revocation of Correspondence	Additional Enclosure(s) (please identify below)		
Express Abandonment Request		l Disclaimer	✓ Postcard		
Information Disclosure Statement	Small E	ntity Statement			
Certified Copy of Priority	Reques	t for Refund			
Document(s)	Remarks]	_		
		to Correct Filing Filing Receipt	g Receipt		
Response to Missing Parts under 37 CFR					
1.52 or 1.53					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm					
or Individual name Ann-Louise Kerner, Ph.D. (Reg. No. 33, 523)					
Signature and-house there					
Date Out. 7, 2001					
CERTIFICATE OF MAILING					
I hereby certify that this correspondence is being deposited with the United States Postal Service <u>as first class mail in an</u> envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: S 7 0					
Typed or printed name Rosemarie Goldman					

Date

0

Signature





PATENT Attorney Docket No. 47508.528

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Agrawal et al.

Examiner: Unknown

Serial No.:

09/845,623

Group Art Unit: 1623

Filed:

April 30, 2001

For:

Modulation of Oligonucleotide CpG-Mediated Immune Stimulation by Positional

Modification of Nucleosides

Commissioner for Patents Office of Initial Patent Examination **Customer Service Center** Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service First Class Mail in an envelope addressed to Commissioner for Patents, Office of Initial Patent Examiner, Washington, D.C. 20231.

REQUEST FOR CORRECTION OF FILING RECEIPT

Attached is a copy of the Official Filing Receipt for the above-identified patent application. The Filing Receipt does not identify the residence of the inventor. The correct information is as follows:

Applicant(s):

Sudhir Agrawal, Shrewsbury Mass.

Attorney Docket No.:

47508.528

The Attached Filing Receipt shows the corrections marked in red ink for your convenience.

It is Applicant's belief that no fee is due for correction of this error. If, however, a fee is required, please charge the appropriate fee to Deposit Account No. 08-0219.


Respectfully submitted,

Dated: Que . 7, 2001

Ann-Louise Kerner, Ph.D.
Registration No. 33,523
Attorney for Applicants

Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109

Tele: (617) 526-6000



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.usplo.gov

ſ	APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
	09/845,623	04/30/2001	1623	413	47508. xxx	3	22	4

CONFIRMATION NO. 2601

FILING RECEIPT

OC00000006228493

Wayne A. Keown, Ph.D. Hale and Dorr LLP 60 State Street Boston, MA 02109-1816

Date Mailed: 06/26/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Sudhir Agrawal, Residence Not Provided; Shrew Sbury Mass.

Domestic Priority data as claimed by applicant

Foreign Applications

If Required, Foreign Filing License Granted 06/26/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides $\frac{1}{RRR} \frac{1}{RRR} \frac{1}{RRR}$

Preliminary Class

E 47508.528	
ction Date.	
ction to be Taken:	(2.78.0

Data entry by : HOANG, SON

Team : OIPE

Date: 06/26/2001





LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231